Login / Signup

Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.

Kjetil BoyeAlessandra LonghiTormod GurenSusanne LorenzStine NæssMichela PieriniIngeborg TaksdalIngvild LobmaierMarilena CesariAnna PaioliAyca M LøndalenElisabetta SetolaIvar HomplandLeonardo A Meza-ZepedaKirsten Sundby HallEmanuela Palmerini
Published in: Cancer immunology, immunotherapy : CII (2021)
In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.
Keyphrases